Subcutaneous anakinra in the management of refractory MIS-C in France
Description
CONCLUSIONS: Subcutaneous anakinra appears to be a safe and effective treatment for the management of heart failure or MAS in MIS-C patients. The value of IVIG in these two situations remains to be reviewed.
